Triclabendazole

Triclabendazole is a prescription medication used for the treatment of Fascioliasis. 

• Triclabendazole is available under the following different brand names: Egaten

Common side effects of Triclabendazole include:

• Stomach pain,
• Diarrhea,
• Upset stomach,
• Vomiting,
• Loss of appetite,
• Increased sweating,
• Dizziness, and
• Headache

Serious side effects of Triclabendazole include:

• Hives,
• Difficulty breathing,
• Swelling of the face, lips, tongue, or throat,
• Rash,
• Red, swollen, blistered, or peeling skin with or without fever,
• Wheezing,
• Tightness in the chest or throat,
• Difficulty swallowing or talking,
• Unusual hoarseness,
• Shortness of breath, and
• Fast heartbeat

Rare side effects of Triclabendazole include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Tablet

• 250 mg

Fascioliasis

Adult dosage

• 10 mg/kg orally for 2 doses administered 12 hours apart
• Tablets are scored and divisible into two halves of 125 mg
• If dosage cannot be adjusted exactly, round the dose upwards

Pediatric dosage

• Pediatric below 6 years: Safety and efficacy not established
• Pediatrics above 6 years
  • 10 mg/kg orally for 2 doses administered 12 hours apart
  • Tablets are scored and divisible into two halves of 125 mg
  • If dosage cannot be adjusted exactly, round the dose upwards

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Triclabendazole has severe interactions with the following drug:
  • mavacamten 
• Triclabendazole has serious interactions with the following drugs:
  • amisulpride
  • bedaquiline
  • buprenorphine
  • ceritinib
  • chloroquine
  • clarithromycin
  • crizotinib
  • desflurane
  • entreating
  • eribulin
  • fexinidazole
  • isoflurane
  • lefamulin
  • oxaliplatin
  • pitolisant
  • sevoflurane
  • siponimod
• Triclabendazole has moderate interactions with at least 123 other drugs.
• Triclabendazole has minor interactions with no other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions or concerns.

Contraindications

• Hypersensitivity to triclabendazole and/or to other benzimidazole derivatives or any of the excipients 

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Triclabendazole?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Triclabendazole?”

Cautions

• Prolongs QTc interval; the magnitude of QTc prolongation can increase with increasing treatment duration; monitor electrocardiogram (ECG) in patients with a history of prolongation of QTc interval or a history of symptoms compatible with a long QT interval or with electrolyte imbalance like hypokalemia, or patients with hepatic impairment; if signs of cardiac arrhythmia occur during treatment, stop treatment and monitor ECG
• Drug interactions overview
  • In vitro data suggest coadministration of triclabendazole and CYP2C19 substrates may increase plasma concentrations of CYP2C19 substrates; potentially elevated concentrations of CYP2C19 substrates are expected to be transient based on the short elimination half-life and short treatment duration of triclabendazole
  • Monitor ECG when used in patients who receive drugs that are known to prolong the QTc interval, or patients taking CYP1A2 inhibitors; if signs of cardiac arrhythmia occur during treatment, stop treatment and monitor ECG

Pregnancy and Lactation

• There are no available data on use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes
• Lactation
  • There are no data on the presence of human milk, its effects on the breastfed infant, or its effects on milk production
  • Published animal data indicate that triclabendazole is detected in goat milk when administered as a single dose to one lactating animal
  • When a drug is present in animal milk, it is likely that the drug will be present in human milk
  • Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or the underlying maternal condition